TOKYO and CAMBRIDGE, Mass., Aug 14, 2024 – (JCN N […]
中国生物制药（1177.HK）公布2024中期业绩
重点成果 – 期内，集团共有4个创新产品获中国国家药品监督管理局（「NMPA」）批准上市，分别为安 […]…
Sino Biopharmaceutical (1177.HK) Announces 2024 Interim Results
Development Highlights – During the reporting Per […]